Friday, 22 Jun 2018

You are here

Inflammatory Arthritis Variants with Checkpoint Inhibitors

Two recently published studies have demonstrated distinctive patterns of rheumatic complaints in patients treated wtih immune checkpoint inhibitors (ICIs).

Capelli and colleagues have studied patients treated with ICIs and found two variants of inflammatory arthritis (IA) - a reactive arthritis like large joint arthritis with combination ICI therapy or a small joint IA with ICI monotherapy.

Inflammatory arthritis (IA) is of several immune-related adverse event (irAE) seen with ICI therapy.

They identified 30 patients with combination ICI therapy who primarily presented with knee arthritis, with high C-reactive protein levels, a prior irAE, and show a a reactive arthritis-like phenotype.

By contrast, those treated with ICI monotherapy were more likely to have initial small joint involvement and to have IA as their only irAE.

Ten patients required additional immunosuppression beyond corticosteroids, with TNF-inhibitors and/or methotrexate. Those on TNF inhibitors did not show tumor progression.

Another French cohort study described the two rheumatic variants in 35 (6.6%) of their 524 ICI treated patients. (Citation source: https://buff.ly/2HV9msa)

All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days.

Patients either exhibited IA that mimicked rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) or they demonstrated non-inflammatory musculoskeletal conditions (2.8%; n=15).

IA patients required glucocorticoids, and methotrexate was started in two patients.

Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy.

They noted that those with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001).

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

More Like This

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.